Skip to main content
. Author manuscript; available in PMC: 2018 Mar 9.
Published in final edited form as: Nanoscale. 2017 Mar 9;9(10):3408–3415. doi: 10.1039/c6nr06948g

Fig. 1.

Fig. 1

Production and characterization of SA-TMV. (A) Schematic representation of conjugation of TMV with SA. SA and TMV-lys are first separately conjugated with PEG linkers through NHS chemistry, followed by conjugation of SA-PEG4-SH and maleimide-PEG4-TMV to produce SA-PEG8-TMV. Analysis of particles before and after conjugation by (B) SDS-PAGE and (C) Western Blot (WB). Free SA was used as a reference for WB analysis. SA conjugation is indicated by the presence of multiple bands with MW > 64 kDa (MW of single TMV-lys CP is ~17 kDa; MW of single SA is ~67 kDa). WB immune recognition by anti-TMV antibodies shown in green, anti-SA antibodies shown in red. (D) Dot blot analysis of immune recognition of TMV and SA-TMV by anti-TMV and anti-cowpea mosaic virus (anti-CPMV, negative control). PBS is an additional negative control. (E) Quantitative densitometric analysis of the dot blots.